Johns Hopkins University — Biomedical Watch V2

Essais liés36clinical trials

VilleBaltimorelocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07164443

Ouvrir le site du centre

Essais cliniques associés

Molécule	Indication / population	Phase	NCT	Titre	Statut
NLY01	SEP	Phase 2	NCT07497399	TAG-MS — Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis	RECRUITING
Maridebart cafraglutide	Insuffisance cardiaque	Phase 3	NCT07037459	MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity	RECRUITING
Active tDCS (tDCS) on DLPFC	Alzheimer	Non applicable	NCT05978804	Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease	TERMINATED
hyaluronidase plus saline	Accident vasculaire cérébral	Phase 2	NCT06718413	Myofascial Dysfunction in Post Stroke Shoulder Pain	RECRUITING
AFSW Guided DOAC	Accident vasculaire cérébral	Phase 3	NCT05836987	REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation	RECRUITING
SPN-817	Épilepsie	Phase 2	NCT06798896	RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures	RECRUITING
Pasritamig	Cancer	Phase 3	NCT07164443	KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)	RECRUITING
GammaTile®	Cancer	Phase 3	NCT07195591	BRIDGES — Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care	RECRUITING
Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy	Épilepsie	À vérifier	NCT02694094	Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy	ACTIVE_NOT_RECRUITING
CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis	SEP	À vérifier	NCT04495556	CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis	ACTIVE_NOT_RECRUITING
Ocrelizumab	SEP	Phase 4	NCT04261790	Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis	COMPLETED
MT-1186	Sclérose latérale amyotrophique	Phase 3	NCT05151471	Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS	TERMINATED
Belimumab	SEP	Phase 2	NCT04767698	Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis	TERMINATED
Intravenously administered pooled human immunoglobulin (IVIG)	Myopathies	Phase 2	NCT06599697	The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy	RECRUITING
Neuraceq	Alzheimer	À vérifier	NCT05617014	ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4	ENROLLING_BY_INVITATION
Edaravone (Radicava®/Radicava ORS®)	Sclérose latérale amyotrophique	À vérifier	NCT04259255	Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)	COMPLETED
Acoramidis	Alzheimer	Phase 3	NCT06563895	Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	RECRUITING
Adalimumab	Parkinson	Phase 2	NCT06996652	PRISMS — An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)	RECRUITING
MT-1186	Sclérose latérale amyotrophique	Phase 3	NCT04165824	Safety Study of Oral Edaravone Administered in Subjects With ALS	COMPLETED
MT-1186	Sclérose latérale amyotrophique	Phase 3	NCT04577404	Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)	COMPLETED
ION363	Sclérose latérale amyotrophique	Phase 3	NCT04768972	FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)	ACTIVE_NOT_RECRUITING
XT-150	Sclérose latérale amyotrophique	Phase 1	NCT06704347	Safety Study of XT-150 in Participants With ALS	NOT_YET_RECRUITING
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)	Sclérose latérale amyotrophique	À vérifier	NCT04363684	ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)	RECRUITING
Pridopidine	Sclérose latérale amyotrophique	Phase 3	NCT07322003	PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS	RECRUITING
Histotripsie — HistoSonics Edison System	Cancer	Non applicable	NCT05820087	The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)	ACTIVE_NOT_RECRUITING
Focal cortical cooling	Épilepsie	Non applicable	NCT06391294	Neuronal and Network Mechanisms of Electrocortical Stimulation	ENROLLING_BY_INVITATION
BHV-7000	Épilepsie	Phase 2/3	NCT06309966	RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy	ACTIVE_NOT_RECRUITING
Ublituximab	SEP	Phase 4	NCT07389590	Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis	RECRUITING
MT-1186	Sclérose latérale amyotrophique	Phase 3	NCT04569084	Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS	TERMINATED
APL-130277	Parkinson	Phase 3	NCT02542696	Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease	COMPLETED
ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity	Alzheimer	À vérifier	NCT01078636	ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity	COMPLETED
Ocrelizumab	SEP	Phase 4	NCT03853746	Short-term B-cell Depletion in Relapsing Multiple Sclerosis	COMPLETED
Living With Frontotemporal Dementia	Alzheimer	À vérifier	NCT01738386	Living With Frontotemporal Dementia	TERMINATED
Ocrelizumab	SEP	À vérifier	NCT03873389	Ocrelizumab Effects on the Metabolome in MS	COMPLETED
Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia	Alzheimer	NA	NCT02675270	Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia	COMPLETED
Zilucoplan	Sclérose latérale amyotrophique	Phase 2/3	NCT04297683	HEALEY ALS Platform Trial - Master Protocol	ACTIVE_NOT_RECRUITING